PBAC Recommendation for amendments to COVID-19 oral treatment restrictions

Page last updated: 10 July 2022

Updated September 2022

The Pharmaceutical Benefits Advisory Committee (PBAC) recommended changes to the Pharmaceutical Benefits Scheme (PBS) eligibility criteria for both molnupiravir (Lagevrio^®) and nirmatrelvir and ritonavir (Paxlovid^®), in the light of current understanding of the evidence for effectiveness and safety of these medicines, recent PBS utilisation patterns, and the changing epidemiology of COVID-19. The PBAC Outcome Statement and updates to the molnupiravir (Lagevrio®) and nirmatrelvir and ritonavir (Paxlovid®) Fact sheets are now available.